89 related articles for article (PubMed ID: 10463583)
1. Antitumor activity of 13,14-dihydro-15-deoxy-delta7-prostaglandin-A1-methyl ester integrated into lipid microspheres against human ovarian carcinoma cells resistant to cisplatin in vivo.
Sasaki H; Niimi S; Akiyama M; Tanaka T; Hazato A; Kurozumi S; Fukushima S; Fukushima M
Cancer Res; 1999 Aug; 59(16):3919-22. PubMed ID: 10463583
[TBL] [Abstract][Full Text] [Related]
2. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
Rose WC; Basler GA
In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
[TBL] [Abstract][Full Text] [Related]
3. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity, optimum administration method and pharmacokinetics of 13,14-dihydro-15-deoxy-deoxy-Delta7 -prostaglandin A1 methyl ester (TEI-9826) integrated in lipid microspheres (Lipo TEI-9826).
Fukushima S; Takeuchi Y; Kishimoto S; Yamashita S; Uetsuki K; Shirakawa S; Suzuki M; Furuta K; Noyori R; Sasaki H; Kikuchi Y; Kita T; Yamori T; Sawada J; Kojima M; Hazato A; Kurozumi S; Fukushima M
Anticancer Drugs; 2001 Mar; 12(3):221-34. PubMed ID: 11290870
[TBL] [Abstract][Full Text] [Related]
5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
6. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
Krieger ML; Eckstein N; Schneider V; Koch M; Royer HD; Jaehde U; Bendas G
Int J Pharm; 2010 Apr; 389(1-2):10-7. PubMed ID: 20060458
[TBL] [Abstract][Full Text] [Related]
7. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
8. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.
Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y
Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292
[TBL] [Abstract][Full Text] [Related]
9. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer.
Wang Z; Cai L; Wang H
Gynecol Oncol; 2005 Mar; 96(3):643-50. PubMed ID: 15721406
[TBL] [Abstract][Full Text] [Related]
11. Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells.
Pors K; Plumb JA; Brown R; Teesdale-Spittle P; Searcey M; Smith PJ; Patterson LH
J Med Chem; 2005 Oct; 48(21):6690-5. PubMed ID: 16220985
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives.
Moebus VJ; Stein R; Kieback DG; Runnebaum IB; Sass G; Kreienberg R
Anticancer Res; 1997; 17(2A):815-21. PubMed ID: 9137413
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
Tayyem H; Huq F; Yu JQ; Beale P; Fisher K
ChemMedChem; 2008 Jan; 3(1):145-51. PubMed ID: 17963210
[TBL] [Abstract][Full Text] [Related]
14. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
15. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II).
Kikuchi Y; Hirata J; Hisano A; Tode T; Kita T; Nagata I
Gynecol Oncol; 1995 Jul; 58(1):11-5. PubMed ID: 7789875
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis and inhibition of angiogenesis by PEGylated liposomal quercetin in both cisplatin-sensitive and cisplatin-resistant ovarian cancers.
Long Q; Xiel Y; Huang Y; Wu Q; Zhang H; Xiong S; Liu Y; Chen L; Wei Y; Zhao X; Gong C
J Biomed Nanotechnol; 2013 Jun; 9(6):965-75. PubMed ID: 23858960
[TBL] [Abstract][Full Text] [Related]
17. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of o/w type emulsions containing antitumor prostaglandin.
Fukushima S; Kishimoto S; Takeuchi Y; Fukushima M
Adv Drug Deliv Rev; 2000 Dec; 45(1):65-75. PubMed ID: 11104898
[TBL] [Abstract][Full Text] [Related]
19. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
[TBL] [Abstract][Full Text] [Related]
20. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]